finasteride and Disease Exacerbation

finasteride has been researched along with Disease Exacerbation in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (5.88)	18.2507
2000's	28 (54.90)	29.6817
2010's	17 (33.33)	24.3611
2020's	3 (5.88)	2.80

Authors

Authors	Studies
Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC	1
Bonaventura, I; Cornfield, T; Duffy, J; Hazlehurst, JM; Hodson, L; Isidori, AM; Marjot, T; Moolla, A; Nikolaou, N; Othonos, N; Pofi, R; Tomlinson, JW; Webster, C; White, S; Woods, C	1
Hu, H; Liang, G; Liu, Z; Yang, J; Yang, Y; Zhang, H; Zhao, F	1
Gradzińska, A; Olszewska, M; Rakowska, A; Rudnicka, L	1
Dynda, D; Gupta, N; Helo, S; Holland, B; McVary, KT; Rogers, T	1
Leverson, GE; Macoska, JA; McVary, KT; Ricke, WA; Uchtmann, KS	1
Biagini, G; Meletti, S; Monti, G; Pugnaghi, M	1
Al Edwan, G; Fleshner, N	1
Beck, AP; Henningson, JN; Lindshield, BL; Opoku-Acheampong, AB; Unis, D	1
Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT	1
De Marzo, AM; Gaonkar, G; Goodman, PJ; Heaphy, CM; Joshu, CE; Lippman, SM; Lucia, MS; Meeker, AK; Peskoe, SB; Platz, EA; Thompson, IM	1
Cai, W; Guo, Y; Jiang, Y; Li, W; Wang, X; Yang, S	1
Bell, CF; DerSarkissian, M; Duh, MS; Lefebvre, P; Swensen, AR; Xiao, Y	1
Cohen, SI	1
Ford, L; Parnes, H; Pinsky, P	1
Adomat, HH; Gleave, ME; Guns, ES; Hendy, SC; Locke, JA; Nelson, CC	1
Kim, J; Li, J	1
Mulders, PF; Pfeiffer, MJ; Schalken, JA	1
Fink, HA; Macdonald, R; Rutks, I; Tacklind, J; Wilt, TJ	1
Kaplan, SA; Kusek, JW; Lee, JY; Meehan, AG	1
Alberts, DS; Bartels, HG; Bartels, PH; Carmignani, G; DeCensi, A; Decobelli, O; Hurle, R; Maffezzini, M; Mazzucchelli, R; Montironi, R; Puntoni, M	1
Carter, HB; Feng, Z; Landis, P; Pierorazio, PM; Ross, AE; Schaeffer, EM; Trock, BJ; Walsh, PC	1
Damjanoski, I; Küfer, R; Müller, J; Rinnab, L; Schnöller, TJ	1
Bergner, D; Cook, TJ; Gray, T; Johnson-Levonas, AO; McConnell, JD; Narayan, P; Quezada, WA; Roehrborn, CG; Saltzman, B; Waldstreicher, J	1
de la Rosette, JJ; Erkens, JA; Herings, RM; Leufkens, HG; Souverein, PC	1
Bittmann, L; Brufsky, A; Kantoff, PW; Kaplan, ID; Kaufman, DS; Manola, J; Oh, WK; Smith, MR	1
Gonzalez, CM; McVary, KT	1
Hanneken, S; Kruse, R; Nöthen, MM; Ritzmann, S	1
Andriole, GL; Bautista, OM; Clarke, HS; Crawford, ED; Diokno, A; Dixon, CM; Foley, JP; Foster, HE; Jacobs, SC; Kaplan, SA; Kreder, KJ; Kusek, JW; Lepor, H; Lieber, MM; Lucia, MS; McConnell, JD; McVary, KT; Menon, M; Milam, DF; Miller, GJ; Nyberg, LM; Ramsdell, JW; Roehrborn, CG; Schenkman, NS; Slawin, KM; Smith, JA	1
Vaughan, ED	1
Kim, ED	1
Hausmann, R; Reich, O; Steif, CG; Thalmann, G	1
Garcia-Cardoso, JV; Gonzalez-Enguita, C; Granizo, JJ; Manzarbeitia, F; Sarasa-Corral, JL; Vela-Navarrete, R	1
Camacho Martínez, F; Moreno-Ramírez, D	1
Bautista, OM; Crawford, ED; Kusek, JW; Lieber, MC; McConnell, JD; Meehan, AG; Noble, WR; Nyberg, LM; Roehrborn, CG; Slawin, KM; Smith, JA; Wilson, SS	1
Epstein, JS	1
Asamoto, M; Cho, YM; Shirai, T; Suzuki, S; Takahashi, S; Tang, M	1
Vale, S	1
Levy, A; Samraj, GP	1
Issa, MM; Kraft, KH	1
Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Weidlich, P	1
Douglas, RC; Lazier, CB; Rittmaster, RS; Thomas, LN; Tindall, DJ; Too, CK	1
Rittmaster, RS; Tindall, DJ	1
Brawley, OW; Thompson, IM	1
Akaza, H; Ideyama, Y; Onozawa, M; Shirai, T; Tsukamoto, S	1
Magoha, GA	1
Bergfeld, W; Culbertson, J; Fiedler, V; Hordinsky, M; Kotey, P; Lucky, A; Meehan, A; Olsen, EA; Pappas, F; Price, VH; Roberts, JL; Savin, R; Waldstreicher, J; Whiting, DA	1
Bruchovsky, N; Crook, JM; Gleave, ME; Godwin, L; Goldenberg, SL; Hoffart, D; Klotz, LH; Sadar, M; Warkentin, M	1
Broering, JM; Carroll, PR; Grossfeld, GD; Latini, D; Lubeck, DP; Small, EJ	1

Reviews

12 review(s) available for finasteride and Disease Exacerbation

Article	Year
5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis. Urology journal, 2021, Apr-11, Volume: 18, Issue:3 Topics: 5-alpha Reductase Inhibitors; Disease Progression; Dutasteride; Finasteride; Humans; Male; Prostatic Neoplasms	2021
Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgens; Animals; Anticarcinogenic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azasteroids; Dihydrotestosterone; Disease Progression; Dutasteride; Epithelial Cells; Finasteride; Humans; Isoenzymes; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Patient Selection; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Stromal Cells	2009
Finasteride for benign prostatic hyperplasia. The Cochrane database of systematic reviews, 2010, Oct-06, Issue:10 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatism; Randomized Controlled Trials as Topic	2010
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current urology reports, 2003, Volume: 4, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Treatment Outcome	2003
[Androgenetic alopecia. Current aspects of a common phenotype]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2003, Volume: 54, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Disease Progression; Enzyme Inhibitors; Female; Finasteride; Genetic Predisposition to Disease; Hair; Hair Follicle; Humans; Male; Middle Aged; Minoxidil; Vasodilator Agents	2003
The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia. Current urology reports, 2004, Volume: 5, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Risk; Urologic Diseases	2004
Benign prostatic hyperplasia: when to 'watch and wait,' when and how to treat. Cleveland Clinic journal of medicine, 2007, Volume: 74 Suppl 3 Topics: Adrenergic alpha-Antagonists; Azasteroids; Diagnosis, Differential; Disease Progression; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Observation; Prostatic Hyperplasia; Time Factors	2007
5alpha-reductase inhibition for men with enlarged prostate. Journal of the American Academy of Nurse Practitioners, 2007, Volume: 19, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Decision Trees; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Long-Term Care; Male; Nurse Practitioners; Nurse's Role; Nursing Assessment; Palpation; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Prostatic Hyperplasia; Severity of Illness Index; Treatment Outcome; Urodynamics	2007
[Benign prostatic hyperplasia: medical therapy]. MMW Fortschritte der Medizin, 2007, Aug-16, Volume: 149, Issue:33-34 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Disease Progression; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Muscarinic Antagonists; Phosphodiesterase Inhibitors; Phytotherapy; Plant Extracts; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome	2007
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. European urology, 2008, Volume: 53, Issue:2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Azasteroids; Clinical Trials as Topic; Disease Progression; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Isoenzymes; Male; Prostatic Neoplasms	2008
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. The Journal of urology, 2008, Volume: 179, Issue:4 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Receptor Antagonists; Azasteroids; Dihydrotestosterone; Disease Progression; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Isoenzymes; Male; Prostate; Prostatic Neoplasms; Receptors, Androgen	2008
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology, 2001, Volume: 58, Issue:2 Suppl 1 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Disease Progression; Drug Administration Schedule; Finasteride; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Orchiectomy; Postoperative Complications; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Treatment Outcome	2001

Trials

15 trial(s) available for finasteride and Disease Exacerbation

Article	Year
Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. The Journal of clinical endocrinology and metabolism, 2020, 09-01, Volume: 105, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adipose Tissue; Adolescent; Adult; Aged; Disease Progression; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Dutasteride; Energy Metabolism; Finasteride; Glucocorticoids; Glucose Clamp Technique; Healthy Volunteers; Humans; Male; Middle Aged; Prednisolone; Prescription Drugs; Proof of Concept Study; Young Adult	2020
Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. The Journal of urology, 2018, Volume: 200, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Cystoscopy; Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Hyperthermia, Induced; Male; Middle Aged; Organ Size; Prostate; Prostatic Hyperplasia; Steam; Time Factors; Treatment Outcome	2018
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. The Journal of urology, 2019, Volume: 202, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Biopsy; Cohort Studies; Disease Progression; Doxazosin; Drug Therapy, Combination; Fibrosis; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors; Treatment Outcome	2019
Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. The Journal of urology, 2014, Volume: 191, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Sexuality; Surveys and Questionnaires; Treatment Outcome; Urination	2014
Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate, 2015, Aug-01, Volume: 75, Issue:11 Topics: 5-alpha Reductase Inhibitors; Biopsy; Chromosomal Instability; Disease Progression; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms; Risk Factors; Stromal Cells; Telomere Homeostasis; Telomere Shortening	2015
Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:3 Topics: Aged; Antineoplastic Agents; Biopsy; Disease Progression; False Positive Reactions; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Placebos; Prostatic Neoplasms	2008
Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. The Journal of urology, 2011, Volume: 185, Issue:4 Topics: 5-alpha Reductase Inhibitors; Disease Progression; Finasteride; Humans; Male; Middle Aged; Organ Size; Prostatic Hyperplasia; Time Factors	2011
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. Urologic oncology, 2013, Volume: 31, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Cell Nucleus; Cost-Benefit Analysis; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Finasteride; Flutamide; Humans; Karyometry; Male; Middle Aged; Preoperative Period; Prospective Studies; Prostate; Prostatic Neoplasms; Treatment Outcome	2013
Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. European urology, 2002, Volume: 42, Issue:1 Topics: Acute Disease; Adult; Area Under Curve; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; ROC Curve; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Retention	2002
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology, 2003, Volume: 62, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Finasteride; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome	2003
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progression; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Severity of Illness Index	2003
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. The Journal of urology, 2006, Volume: 175, Issue:4 Topics: Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebo Effect; Prostatic Hyperplasia; Treatment Outcome	2006
The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial. Cancer treatment and research, 1996, Volume: 88 Topics: 5-alpha Reductase Inhibitors; Androgens; Antineoplastic Agents; Chemoprevention; Combined Modality Therapy; Disease Progression; Eflornithine; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk Factors; Vitamins	1996
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology, 2000, Volume: 43, Issue:5 Pt 1 Topics: Administration, Oral; Adult; Alopecia; Biopsy; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Finasteride; Humans; Middle Aged; Postmenopause; Scalp; Treatment Outcome	2000
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Molecular urology, 2000,Fall, Volume: 4, Issue:3 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclic AMP-Dependent Protein Kinases; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Receptors, Androgen; Signal Transduction; Testosterone; Time Factors; Tosyl Compounds	2000

Other Studies

24 other study(ies) available for finasteride and Disease Exacerbation

Article	Year
Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA network open, 2021, 11-01, Volume: 4, Issue:11 Topics: Aged; Aged, 80 and over; Disease Progression; Doxazosin; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Finasteride; Follow-Up Studies; Frail Elderly; Frailty; Geriatric Assessment; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Proportional Hazards Models; Prostatic Hyperplasia; Severity of Illness Index; Urological Agents	2021
Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases. Journal of drugs in dermatology : JDD, 2017, Oct-01, Volume: 16, Issue:10 Topics: Acitretin; Administration, Oral; Alopecia; Dermatologic Agents; Disease Progression; Female; Finasteride; Humans; Isotretinoin; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome	2017
Temporal lobe epilepsy exacerbation during pharmacological inhibition of endogenous neurosteroid synthesis. BMJ case reports, 2013, Feb-19, Volume: 2013 Topics: 5-alpha Reductase Inhibitors; Anticonvulsants; Brain; Disease Progression; Electroencephalography; Epilepsy, Temporal Lobe; Female; Finasteride; Follow-Up Studies; Humans; Lamotrigine; Middle Aged; Neurotransmitter Agents; Time Factors; Triazines	2013
5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk? Current urology reports, 2013, Volume: 14, Issue:3 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Disease Progression; Dutasteride; Finasteride; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Watchful Waiting	2013
Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice. PloS one, 2013, Volume: 8, Issue:10 Topics: 5-alpha Reductase Inhibitors; Animals; Azasteroids; Body Weight; Cholestenone 5 alpha-Reductase; Disease Progression; Dutasteride; Finasteride; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Inbred C57BL; Prostatic Neoplasms; Receptors, Tumor Necrosis Factor, Member 25	2013
Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Medical science monitor : international medical journal of experimental and clinical research, 2015, Oct-03, Volume: 21 Topics: Adrenergic alpha-Antagonists; Biomarkers, Tumor; CD3 Complex; Chronic Disease; Cross-Sectional Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Finasteride; Gene Expression Regulation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Inflammation; Interleukin-6; Lower Urinary Tract Symptoms; Male; Molecular Chaperones; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Transurethral Resection of Prostate; Tumor Necrosis Factor-alpha	2015
Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:10 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Dutasteride; Finasteride; Health Care Costs; Humans; Longitudinal Studies; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; Treatment Outcome; United States; Urinary Retention	2016
Jim's Prostate Cancer. Texas Heart Institute journal, 2017, Volume: 44, Issue:1 Topics: 5-alpha Reductase Inhibitors; Biopsy; Clinical Decision-Making; Disease Progression; Finasteride; Humans; Kallikreins; Male; Neoplasm Grading; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome; Watchful Waiting	2017
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. The Journal of steroid biochemistry and molecular biology, 2009, Volume: 115, Issue:3-5 Topics: Androgen Antagonists; Androgens; Anilides; Animals; Castration; Cell Line, Tumor; Cinnamates; Disease Progression; Drug Combinations; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Ketoconazole; Male; Mice; Mice, Nude; Mifepristone; Molecular Structure; Neoplasm Transplantation; Nitriles; Progesterone; Prostatic Neoplasms; Steroids; Tosyl Compounds; Transplantation, Heterologous	2009
An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. The Prostate, 2010, Oct-01, Volume: 70, Issue:14 Topics: Androgen Antagonists; Androgens; Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cholesterol Side-Chain Cleavage Enzyme; Disease Progression; DNA Primers; Finasteride; Humans; In Situ Hybridization, Fluorescence; Male; Mice; Mice, SCID; Polymerase Chain Reaction; Prostatic Neoplasms; RNA, Messenger; Serine Endopeptidases; Steroids	2010
Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU international, 2012, Volume: 110, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Azasteroids; Biopsy; Disease Progression; Dutasteride; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies	2012
[Histopathology reports of findings of prostate needle biopsies. Individual treatment]. Der Urologe. Ausg. A, 2013, Volume: 52, Issue:2 Topics: Adenocarcinoma; Attitude of Health Personnel; Biomarkers, Tumor; Biopsy, Needle; Cell Proliferation; Cooperative Behavior; Decision Support Techniques; Disease Progression; Finasteride; Germany; Guideline Adherence; Humans; Interdisciplinary Communication; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Palliative Care; Patient Care Planning; Phosphodiesterase 5 Inhibitors; Precision Medicine; Prognosis; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Surveys and Questionnaires	2013
Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. European urology, 2003, Volume: 43, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Risk Factors	2003
Medical management of benign prostatic hyperplasia--are two drugs better than one? The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Severity of Illness Index	2003
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination]. Aktuelle Urologie, 2004, Volume: 35, Issue:5 Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Disease Progression; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors	2004
Finasteride with doxazosin to reduce BPH progression. The Nurse practitioner, 2005, Volume: 30, Issue:3 Topics: Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia	2005
The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU international, 2005, Volume: 96, Issue:7 Topics: 5-alpha Reductase Inhibitors; Adenoma; Adrenergic alpha-Antagonists; Age Factors; Aged; Chi-Square Distribution; Cross-Sectional Studies; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Patient Selection; Phytotherapy; Prostate; Prostatectomy; Prostatic Hyperplasia; Retrospective Studies	2005
Frontal fibrosing alopecia: a survey in 16 patients. Journal of the European Academy of Dermatology and Venereology : JEADV, 2005, Volume: 19, Issue:6 Topics: Aged; Alopecia; Diagnosis, Differential; Disease Progression; Enzyme Inhibitors; Eyebrows; Female; Fibrosis; Finasteride; Glucocorticoids; Humans; Middle Aged; Minoxidil; Postmenopause; Scalp Dermatoses; Treatment Outcome	2005
Evolution of techniques in hair transplantation: a 12-year perspective. Facial plastic surgery : FPS, 2007, Volume: 23, Issue:1 Topics: Adult; Alopecia; Cosmetic Techniques; Disease Progression; Enzyme Inhibitors; Female; Finasteride; Forecasting; Hair; Hair Follicle; Humans; Male; Marketing of Health Services; Middle Aged; Minoxidil; Scalp; Surgical Flaps; Tissue Expansion	2007
Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate cancer and prostatic diseases, 2007, Volume: 10, Issue:4 Topics: Adenocarcinoma; Androgen Antagonists; Animals; Animals, Genetically Modified; Antigens, Viral, Tumor; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide; Male; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Testosterone	2007
Re: expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. T. Kurahashi, H. Miyake, I. Hara and M. Fujisawa J Urol 2007; 177: 757-761. The Journal of urology, 2007, Volume: 178, Issue:1 Topics: 5-alpha Reductase Inhibitors; Disease Progression; Enzyme Inhibitors; Finasteride; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Molecular Chaperones; Neoplasm Proteins; Prostate; Prostatic Neoplasms; Quercetin; Up-Regulation	2007
A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer, 1998, Feb-01, Volume: 82, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adenocarcinoma; Aminobiphenyl Compounds; Androgen Antagonists; Anilides; Animals; Carcinogens; Disease Progression; Enzyme Inhibitors; Finasteride; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Testosterone; Tosyl Compounds	1998
Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia. East African medical journal, 1998, Volume: 75, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Disease Progression; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Urinary Retention; Urodynamics	1998
[Benign prostatic hyperplasia. Finasteride controls progression of BPH]. MMW Fortschritte der Medizin, 2000, Jun-22, Volume: 142, Issue:25 Topics: Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	2000